Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 17Cholangiocarcinoma 13Biliary Tract Neoplasms 13Small Cell Lung Carcinoma 12Triple Negative Breast Neoplasms 8Breast Neoplasms 8Neoplasms 6Neoplasm Metastasis 5Liver Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Pancreatic Neoplasms 4Carcinoma 4Non-Muscle Invasive Bladder Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma Of Esophagus 3Pathologic Complete Response 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Advanced Biliary Tract Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Vaccinia 1SCLC, Limited Stage 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

pembrolizumab 2durvalumab 2Gemcitabine 2Cisplatin 2surufatinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Advanced Biliary Tract Cancer × durvalumab × Clear all
NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
604 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT06708858 2024-11-27

Phase â…¡ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡